SHTDF (Sinopharm Group Co) ROCE % : 10.75% (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sinopharm Group Co's annualized ROCE % for the quarter that ended in Dec. 2024 was 10.75%.

Sinopharm Group Co ROCE % Historical Data

The historical data trend for Sinopharm Group Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co ROCE % Chart

Sinopharm Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

19.76

18.82

17.19

16.35

11.66

Sinopharm Group Co Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial															19.18	15.61	17.19	12.33	10.75

Sinopharm Group Co ROCE % Calculation

Sinopharm Group Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	2298.534	/	( ( (53695.253 - 33821.271)	+	(53955.148 - 34388.944) )	/ 2 )
	=	2298.534	/	( (19873.982	+	19566.204)	/ 2 )
	=	2298.534	/	19720.093
	=	11.66 %

Sinopharm Group Co's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	2136.614	/	( ( (59214.456 - 39041.984)	+	(53955.148 - 34388.944) )	/ 2 )
	=	2136.614	/	( ( 20172.472	+	19566.204 )	/ 2 )
	=	2136.614	/	19869.338
	=	10.75 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

Sinopharm Group Co (OTCPK:SHTDF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sinopharm Group Co ROCE % Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SHTDY:USA 01099:Hong Kong X2S:Germany X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

From GuruFocus

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon • 05-19-2016

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 01-25-2021

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 07-30-2020

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon • 05-19-2016

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon • 10-18-2014

Arnold Van Den Berg Buys Prem Watsa's Fairfax India, 3 Other Stocks in 3rd Quarter

By Holly LaFon Holly LaFon • 10-31-2017

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan • 10-20-2014

Sinopharm Group Co Ltd's Dividend Analysis

By GuruFocus Research • 06-17-2024